Ehrlich Christopher B's Form 4 filing
eFFECTOR Therapeutics, Inc.EFTR · filed Feb 22, 2022
- Accession no.
- 0001209191-22-011731
- Filed
- Feb 22, 2022
- Trade date
- Feb 14-18, 2022
- Filing delay
- 8 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $13.2K. It was filed 8 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ehrlich Christopher BCIK 0001293973 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 14, 2022 | Common Stock | PPurchaseAcquired | +2,000 | $4.45F1 | +$8,900 | 15,000 | Direct | |
| Feb 18, 2022 | Common Stock | PPurchaseAcquired | +1,000 | $4.30 | +$4,300 | 16,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were purchased in two transactions at prices ranging from $4.40 to $4.50. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.